Skip to main content

Antifungal Prophylaxis of Invasive Fungal Infections

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
ItraconazolePhase 3Small Molecule1 trial
Active Trials
NCT00289991Completed489Est. Feb 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerItraconazole

Clinical Trials (1)

Total enrollment: 489 patients across 1 trials

NCT00289991PfizerItraconazole

Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

Start: Mar 2006Est. completion: Feb 2009489 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.